CD19 CAR T-Cell Therapy in Autoimmune Disease - A Case Series with Follow-up. N Engl J Med. 2024 Feb 22;390(8):687-700. 关于BioBro大师兄 BioBro大师兄是一个聚焦生物医药领域产学研的共享平台,包括专业交流以及干货内容和供应链信息分享,持续关注细胞治疗、基因治疗、干细胞药物、抗体药物等领域的前...
[1] Müller F, Taubmann J, Bucci L, et al. CD19 CAR T-Cell Therapy in Autoimmune Disease ...
以及来自德国的团队的研究证实,在髓过氧化物酶(MPO-ANCA)血管炎小鼠模型中,CD19 CAR-T疗法能有效减少B细胞和浆母细胞的数量,进而防止肾组织损伤,为对传统治疗无响应的患者提供了新的治疗途径。
近日,国际顶级期刊NEJM(The New England Journal of Medicine)发表了一篇题为“CD19 CAR T-Cell Therapy in Autoimmune Disease-A Case Series with Follow-up.”的文章。来自德国埃尔兰根大学医院研究人员使用 CAR-T细胞疗法治疗15名患有严重...
The broad, deep, and short duration of B-cell depletion possible with anti-CD19 CAR T-cell therapy may provide sustained treatment-free remission for patients with autoimmune disease; however, the immunological impact of CAR T-cell therapy remains unclear. Objectives: In this study, we evaluated...
CAR-T cell therapyNK cellsNKG2AFcγ receptorThe high potential of CD19.CAR-T cells to treat autoimmune diseases such as Systemic Sclerosis (SSc) supposedly relies on the disappearance of autoantibodies. Here we investigated effects of CAR-T cells on the innate immune system which is an ...
Munoz L, Gerlach RG, Schäfer S, Grieshaber-Bouyer R, Korganow AS, Farge-Bancel D, Mougiakakos D, Bozec A, Winkler T, Krönke G, Mackensen A, Schett G. CD19 CAR T-Cell Therapy in Autoimmune Disease – A Case Series with Follow-up. N Engl J Med. 2024 Feb 22;390(8):687-...
Advancements and challenges in CAR T cell therapy in autoimmune diseases 2024, Nature Reviews Rheumatology Successful use of anti-CD19 CAR T cells in severe treatment-refractory stiff-person syndrome 2024, Proceedings of the National Academy of Sciences of the United States of America EULAR recommenda...
Methods:Patients with treatment-refractory SLE, IIM and SSc were eligible if they had signs of active organ involvement, failure of multiple immunomodulatory therapies, and serious or immediately life-threatening disease. CAR T cell therapy was offered via an expanded access program. Autologous CD19 ...
Anti-CD19 CAR T cells were among the last decade’s scientific breakthroughs, achieving remarkable remissions in patients with B cell leukemias and lymphomas. Now, the engineered cell therapies are traversing disease indications into autoimmunity and resolving disease symptoms in patients with systemic ...